Bucking trends.
Backed by experience. 

Miguel de los Rios, PhD is trained in protein engineering and polymer biophysical chemistry and is the founder and Chief Executive Officer of both Endeavor Biomedicines and RIFT Biotherapeutics. He’s also Vice President of Research and Development at Sevion Therapeutics, a publicly traded therapeutics company with a focus in oncology and autoimmune disorders. Previously, Miguel founded Chimeros, Inc., a venture-backed biologics therapeutic company. At Chimeros, he served as both the CEO as well as the CSO from 2003-2011 and was the inventor of the company’s core technologies.

Dr. Rivka Kreitman is a proven biopharmaceutical executive, with over 35 years of broad academic and pharma experience. Dr. Kreitman had a successful career in Teva Pharmaceutical Industries, with 26 years of experience at different roles spanning the entire drug development spectrum: preclinical pharmacology, clinical studies, project management, regulatory affairs, and R&D. As the Head of Global R&D, Dr. Kreitman oversaw the development of multiple MS drugs.

Revere Kinkel, MD, is Director of the multiple sclerosis program at UCSD Health and leads the program’s clinical, research, and educational efforts within the Department of Neurosciences. Dr. Kinkel is an internationally recognized expert in MS with extensive experience in MS clinical trials. Prior to UCSD, Dr. Kinkel also served as Medical Director of the Mellen Center for Multiple at Cleveland Clinic, Division Chief for the section of demyelinating diseases at Beth Israel Deaconess Medical Center in Boston, and Associate Professor of Neurology at Harvard Medical School. In 2013, Dr. Kinkel received the Walter Cove Award for Innovation from the Accelerated Cure Project for his work in MS.

Robert Eastlack, MD, is the Director of Spine Research at Scripps Clinic and Associate Director of San Diego Spine Fellowship at San Diego Center for Spinal Disorders. Dr. Eastlack is a spinal surgeon with over 15 years of experience in surgical management of spinal cord injury patients. His experience in human spinal cord injury case management, as well as spinal cord injury clinical trials, make Dr. Eastlack an invaluable asset to the Novoron team.

Jeffrey Goldberg, MD, PhD is professor and Chair of Ophthalmology at the Byers Eye Institute at Stanford University. Dr. Goldberg received his BS (magna cum laude) from Yale University and his MD and PhD from Stanford University, where he made significant discoveries about the failure of optic nerve regeneration. He was named the 2010 Scientist of the Year by the Hope for Vision foundation and received the Cogan award from the Association for Research in Vision and Ophthalmology in 2012.

For the last 20 years, Bryn Martin, PhD, has studied cerebrospinal fluid (CSF) diseases, diagnostics, and therapeutics. He is considered a leading expert on targeted CSF drug delivery. Dr. Martin has published 65+ peer-reviewed papers in the field and served as Principle Investigator for research funded by National Institute of Health (NIH), National Aeronautics and Space Administration (NASA), National Science Foundation (NSF), industry, and foundations within the field. He currently serves as Vice President of Research, Drug Delivery and CSF Sciences for Alcyone Therapeutics and Adjunct Associate Professor of Mechanical, Chemical, and Biological Engineering at University of Idaho.